{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:30Z","timestamp":1791228690210,"version":"4.1.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This article highlights and emphasizes how new knowledge of mechanisms linked to the interleukin-23 (IL-23)\/IL-17 pathway is relevant to the pathophysiology of axial spondyloarthritis (axSpA) and demonstrates how molecules in IL-23\/IL-17 pathway provide novel therapeutic targets for axSpA patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Similarly to ankylosing spondylitis (AS), the increased frequency of Th17 cells in nr-axSpA patients underscores the concept that these disorders can be viewed on a spectrum. Recent findings suggest that the contribution of IL-23\/IL-17 signaling pathways possibly differs in male and female AS patients. The finding that IL-17 and IL-22 secreting-type 3 innate lymphoid cells are increased in AS patients point to their potential role in the pathogenesis of axSpA. Reports of dysbiosis in the gut microbiome of AS patients support previous work indicating a possible causal relationship between altered gut flora, ileocolonic inflammation and axSpA. Of important clinical relevance are results from clinical trials supporting the efficacy and safety of agents that block IL-12\/23 (ustekinumab) and IL-17 (secukinumab and ixekizumab) in AS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Recent studies further establish the central position of the IL-23\/IL-17 pathway in the pathogenesis of axSpA. Targeting the IL-23\/IL-17 pathway appears to be a safe and effective strategy for treatment of axSpA patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000301","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T11:34:21Z","timestamp":1463052861000},"page":"359-367","source":"Crossref","is-referenced-by-count":56,"title":["Targeting the interleukin-23\/17 axis in axial spondyloarthritis"],"prefix":"10.1097","volume":"28","author":[{"given":"Ananta","family":"Paine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/acr.21621","article-title":"Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey","volume":"64","author":"Reveille","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13075-015-0897-6","article-title":"Comparison of nonradiographic axial spondyloarthritis and ankylosing spondylitis patients - baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice","volume":"17","author":"Wallman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI63681","article-title":"IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis","volume":"123","author":"Huber","year":"2013","journal-title":"J Clin Invest"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nri3726","article-title":"Interactions between innate and adaptive lymphocytes","volume":"14","author":"Gasteiger","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature11984","article-title":"Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1","volume":"496","author":"Wu","year":"2013","journal-title":"Nature"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.4049\/jimmunol.0900732","article-title":"Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells","volume":"182","author":"Awasthi","year":"2009","journal-title":"J Immunol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","article-title":"Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling","volume":"467","author":"Ghoreschi","year":"2010","journal-title":"Nature"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat Genet"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1073\/pnas.1017854108","article-title":"Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses","volume":"108","author":"Sarin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PloS One"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis-insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1038\/srep10314","article-title":"Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways","volume":"5","author":"Uddin","year":"2015","journal-title":"Sci Rep"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.33321","article-title":"Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats","volume":"64","author":"Glatigny","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/s10165-009-0166-0","article-title":"Ankylosing enthesitis associated with up-regulated IFN-gamma and IL-17 production in (BXSB x NZB) F(1) male mice: a new mouse model","volume":"19","author":"Abe","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13075-015-0805-0","article-title":"Inflammation-driven bone formation in a mouse model of ankylosing spondylitis: sequential not parallel processes","volume":"18","author":"Tseng","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916934.2014.976630","article-title":"Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice","volume":"48","author":"Ebihara","year":"2015","journal-title":"Autoimmunity"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"e31000","DOI":"10.1371\/journal.pone.0031000","article-title":"Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis","volume":"7","author":"Zhang","year":"2012","journal-title":"PloS One"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","article-title":"Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis","volume":"74","author":"Wendling","year":"2007","journal-title":"Joint Bone Spine"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R28-20230829","first-page":"17362","article-title":"Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00296-009-0883-x","article-title":"Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis","volume":"29","author":"Wang","year":"2009","journal-title":"Rheumatol Int"},{"key":"R30-20230829","first-page":"621","article-title":"Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the relationship with disease activity","volume":"77","author":"Ugur","year":"2015","journal-title":"Nagoya J Med Sci"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J Immunol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","article-title":"IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities","volume":"54","author":"Jansen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","article-title":"Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response","volume":"13","author":"Appel","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/kes267","article-title":"Decreased Th17 and Th1 cells in the peripheral blood of patients with early nonradiographic axial spondyloarthritis: a marker of disease activity in HLA-B27(+) patients","volume":"52","author":"Bautista-Caro","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/annrheumdis-2012-202431","article-title":"Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies","volume":"72","author":"van der Horst-Bruinsma","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.39464","article-title":"Sexual dimorphism in the Th17 signature of ankylosing spondylitis","volume":"68","author":"Gracey","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.39261","article-title":"Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clim.2015.05.001","article-title":"Gut microbes, immunity, and spondyloarthritis","volume":"159","author":"Stoll","year":"2015","journal-title":"Clin Immunol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/ar4228","article-title":"Microbes, the gut and ankylosing spondylitis","volume":"15","author":"Costello","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.24763","article-title":"HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats","volume":"60","author":"DeLay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"e105684","DOI":"10.1371\/journal.pone.0105684","article-title":"HLA-B27 and human beta2-microglobulin affect the gut microbiota of transgenic rats","volume":"9","author":"Lin","year":"2014","journal-title":"PloS One"},{"key":"R44-20230829","article-title":"Intestinal dysbiosis in ankylosing spondylitis","author":"Costello","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","article-title":"Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases","volume":"104","author":"Frank","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R47-20230829","first-page":"1","article-title":"Fungal microbiota dysbiosis in IBD","volume":"0","author":"Sokol","year":"2016","journal-title":"Gut"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","article-title":"The treatment-naive microbiome in new-onset Crohn's disease","volume":"15","author":"Gevers","year":"2014","journal-title":"Cell Host Microbe"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","article-title":"Induction of intestinal Th17 cells by segmented filamentous bacteria","volume":"139","author":"Ivanov","year":"2009","journal-title":"Cell"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nature13279","article-title":"Focused specificity of intestinal TH17 cells towards commensal bacterial antigens","volume":"510","author":"Yang","year":"2014","journal-title":"Nature"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/annrheumdis-2013-203854","article-title":"Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort","volume":"73","author":"Van Praet","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/kev245","article-title":"Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation","volume":"55","author":"Wright","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheum"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","article-title":"Open label trial of anakinra in active ankylosing spondylitis over 24 weeks","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14712598.2014.890587","article-title":"Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis","volume":"14","author":"Weitz","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","article-title":"Ustekinumab, an anti-il-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled psummit-1 and psummit-2 trials","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Antiinterleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","article-title":"Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study","volume":"75","author":"Baraliakos","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2016","journal-title":"MAbs"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1073\/pnas.1501956112","article-title":"CBP30, a selective CBP\/p300 bromodomain inhibitor, suppresses human Th17 responses","volume":"112","author":"Hammitzsch","year":"2015","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201607000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:35:25Z","timestamp":1693290925000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201607000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000301","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}